GlassScriptPhysician profile
Timothy M Carey
NPI 1174725345
$13,653.91
in general payments reported to CMS, 2019-2025
66 companies · $1,696 in 2025
The $1,696 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,560 · 2020: $1,578 · 2021: $2,232 · 2022: $2,493 · 2023: $1,856 · 2024: $2,239 · 2025: $1,696.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,591 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,591.11 |
| Education | $200.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,161.48 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $771.62 | 2019-2024 | Keytruda, Lynparza |
| Pfizer INC. | $757.63 | 2019-2025 | |
| Glaxosmithkline, LLC. | $586.06 | 2020-2025 | Jemperli, Zejula, Ojjaara |
| Daiichi Sankyo INC. | $565.64 | 2019-2025 | Enhertu, Injectafer, Datroway |
| Janssen Biotech, INC. | $562.15 | 2019-2024 | Talvey, Darzalex, Tecvayli |
| Genzyme Corporation | $543.24 | 2019-2025 | |
| Abbvie INC. | $527.49 | 2019-2025 | Venclexta |
| Celgene Corporation | $522.52 | 2019-2025 | Reblozyl, Opdualag, Pomalyst |
| E.R. Squibb & Sons, L.L.C. | $504.33 | 2019-2025 | Opdivo |
| Astrazeneca Pharmaceuticals LP | $424.58 | 2019-2025 | Enhertu |
| Amgen INC. | $407.68 | 2019-2023 | Xgeva, Nplate, Vectibix |
| Genentech USA, INC. | $405.16 | 2019-2025 | Polivy, Columvi, Lunsumio |
| Pharmacyclics LLC, An Abbvie Company | $396.36 | 2019-2023 | Imbruvica |
| Incyte Corporation | $346.16 | 2019-2025 | Jakafi, Monjuvi |
Show all 66 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $316.32 | 2019-2025 | |
| Gilead Sciences, INC. | $307.17 | 2021-2025 | Trodelvy |
| Exelixis INC. | $303.42 | 2021-2025 | Cabometyx |
| Takeda Pharmaceuticals U.S.A., INC. | $287.67 | 2019-2025 | Iclusig, Fruzaqla |
| Regeneron Healthcare Solutions, INC. | $280.39 | 2020-2025 | Libtayo |
| Astellas Pharma US INC | $247.72 | 2019-2025 | Padcev, Xtandi, Xospata |
| Seagen INC. | $245.23 | 2020-2023 | Adcetris |
| Jazz Pharmaceuticals INC. | $242.30 | 2020-2025 | |
| Deciphera Pharmaceuticals INC. | $224.21 | 2020-2025 | Qinlock, Tgct, Romvimza |
| Array Biopharma INC | $223.72 | 2019-2025 | Braftovi, Mektovi, Tukysa |
| Puma Biotechnology, INC. | $208.01 | 2020-2025 | |
| Eisai INC. | $195.04 | 2020-2024 | |
| Lilly USA, LLC | $192.52 | 2019-2024 | Verzenio, Jaypirca, Retevmo |
| Emd Serono, INC. | $134.18 | 2019-2024 | Tepmetko |
| Octapharma USA, INC. | $126.04 | 2020 | |
| Coherus Oncology, INC. | $121.30 | 2020-2023 | |
| Stemline Therapeutics INC. | $105.81 | 2023-2025 | Orserdu |
| Tersera Therapeutics LLC | $105.17 | 2020-2025 | Zoladex |
| Blueprint Medicines Corporation | $102.93 | 2020-2025 | Ayvakit |
| Kite Pharma, INC. | $89.88 | 2021-2025 | Yescarta |
| Pharmaessentia USA Corporation | $89.82 | 2022-2025 | Besremi |
| Rigel Pharmaceuticals, INC. | $88.12 | 2019-2024 | Rezlidhia, Tavalisse |
| Karyopharm Therapeutics INC. | $66.68 | 2020-2023 | Xpovio |
| Adc Therapeutics America, INC. | $56.77 | 2022-2024 | |
| Morphosys, US INC. | $54.21 | 2022-2023 | Monjuvi |
| Aveo Pharmaceuticals, INC. | $51.41 | 2022-2024 | |
| Beigene USA, INC. | $51.04 | 2023-2025 | Tevimbra, Brukinsa |
| Fennec Pharmaceuticals, INC. | $49.34 | 2024 | Pedmark |
| Pharmacosmos Therapeutics INC. | $45.72 | 2025 | Monoferric |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.71 | 2021-2023 | Gilotrif |
| Mirati Therapeutics, INC. | $44.33 | 2023 | Krazati |
| Myovant Sciences INC. | $42.79 | 2021 | |
| Organon LLC | $41.98 | 2022-2023 | Ontruzant |
| Servier Pharmaceuticals LLC | $36.41 | 2023-2024 | |
| Amag Pharmaceuticals, INC. | $29.27 | 2019 | |
| Azurity Pharmaceuticals, INC. | $28.69 | 2025 | Danziten |
| Myriad Genetic Laboratories, INC. | $28.32 | 2021 | |
| Adaptive Biotechnologies Corporation | $26.84 | 2025 | Clonoseq |
| Kyowa Kirin, INC. | $25.99 | 2019 | |
| Alexion Pharmaceuticals, INC. | $25.02 | 2021-2022 | |
| Cti Biopharma Corp. | $23.31 | 2023 | Vonjo |
| Acrotech Biopharma INC. | $22.44 | 2023 | Beleodaq |
| Sun Pharmaceutical Industries INC. | $18.40 | 2019 | |
| Geron Corporation | $18.38 | 2024 | Rytelo |
| Taiho Oncology, INC. | $17.90 | 2020 | |
| Agios Pharmaceuticals, INC. | $14.61 | 2022 | |
| Sobi, INC | $14.58 | 2024 | |
| Dova Pharmaceuticals | $14.40 | 2020 | |
| Epizyme, INC. | $14.02 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $13.89 | 2020 | |
| Heron Therapeutics, INC. | $12.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Carey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.